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Purpose: A Phase I dose-escalation study was performed to determine the maximum   tolerated 
dose (MTD) of the immunotoxin VB4-845 in patients with nonmuscle-invasive bladder cancer 
(NMIBC) refractory to or intolerant of bacillus Calmette–Guerin (BCG). Secondary objectives 
included evaluation of the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy 
of VB4-845.
Patients and methods: Sixty-four patients with Grade 2 or 3, stage Ta or T1 transitional cell 
carcinoma or in situ carcinoma, either refractory to or intolerant of BCG therapy, were enrolled. 
Treatment was administered in ascending dose cohorts ranging from 0.1 to 30.16 mg. After 
receiving weekly instillations of VB4-845 to the bladder via catheter for 6 consecutive weeks, 
patients were followed for 4–6 weeks post-therapy and assessed at week 12.
Results: An MTD was not determined, as a dose-limiting toxicity was not identified over the dose 
range tested. VB4-845 therapy was safe and well tolerated with most adverse events reported as 
mild; as a result, no patients were removed from the study in response to toxicity. By the end of 
the study, the majority of patients had developed antibodies to the exotoxin portion of VB4-845. 
A complete response was achieved in 39% of patients at the 12-week time point.
Conclusions: VB4-845 dosed on a weekly basis for 6 weeks was very well tolerated at all 
dose levels. Although an MTD was not determined at the doses administered, VB4-845 showed 
evidence of an antitumor effect that warrants further clinical investigation for the treatment of 
NMIBC in this patient population.
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Introduction
Bladder cancer is the fourth most common malignancy in men and the ninth most 
common in women, with an estimated incidence of 67,160 and 13,750 estimated deaths 
(2007) in the United States. Transitional cell carcinoma (TCC) refers to those bladder 
cancer tumors derived from urothelial tissue, more than 90% of which originate in the 
urinary bladder and present as nonmuscle-invasive disease in the majority of patients 
at diagnosis.1 Of those patients who respond to current standard of care, approximately 
two-thirds will have recurrence, and 10%–20% of recurrent tumors will have progressed 
to muscle-invasive disease.2 Typically, treatment for high-risk, nonmuscle-invasive 
bladder cancer (NMIBC) is transurethral resection of the bladder tumor and adjuvant 
therapy with bacillus Calmette–Guerin (BCG). Although BCG treatment can reduce 
the risk of recurrence and progression, its use is limited by the adverse effect profile 
and intolerance that occurs in 20% of patients.3–6Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Epithelial cell adhesion molecule (EpCAM) is overex-
pressed in many carcinomas relative to their normal tissue 
counterparts, as is the case in TCC.7,8 In addition, EpCAM 
expression increases as these cancers progress from lower 
to higher grades.8–11 Together, these features make EpCAM 
a clinically relevant antigen for targeted therapy in bladder 
cancer.
VB4-845 is a recombinant fusion protein that targets 
EpCAM-positive cancer cells. It consists of an anti-EpCAM 
humanized single-chain variable fragment (scFv) linked to 
a truncated form of Pseudomonas exotoxin A (ETA252–608) 
that lacks the cell-binding domain.12 Once bound to EpCAM 
on the surface of carcinoma cells, VB4-845 is internalized, 
whereupon the exotoxin portion of the fusion protein induces 
apoptosis.13,14
One concern of targeted therapies has been the toxicity 
associated with systemic administration of this class of 
drug.15 Moreover, repeated use of therapeutics comprising 
foreign proteins is limited by their immunogenicity. There-
fore, it is desirable to develop therapies designed for local 
administration, thereby increasing the clinical benefit of 
these treatments while minimizing any drug-related effects. 
Accordingly, locoregional delivery of ETA-conjugated 
antibodies has been demonstrated to be well tolerated and 
clinically effective in patients with glioblastoma multiforme, 
ErbB2-expressing breast tumors, and squamous cell carci-
noma of the head and neck.16–18 Nonclinical studies showed 
a significant reduction in toxicity with locally administered 
VB4-845. Similarly, local injections of VB4-845 were well 
tolerated in Cynomolgus monkeys with adverse events 
(AEs) being mild and easily managed.19 In addition to the 
strong nonclinical safety profile, VB4-845 exhibits highly 
potent activity against EpCAM-expressing tumor cell lines 
and has been shown to localize to EpCAM-positive tumor 
xenografts.12 Based on these preclinical results, a Phase I 
dose-escalation trial was performed using VB4-845 as an 
intravesical therapy in BCG-refractory and BCG-intolerant 
patients with Grade 2 or 3 NMIBC.
Patients and methods
Patient selection
Only patients 18 years of age or older with immuno-
histochemically confirmed EpCAM-positive Grade 2 
or 3 NMIBC (Ta, T1, in situ carcinoma [TIS]), either 
refractory to (recurrence within 2 years following at 
least one complete cycle of BCG therapy) or intol-
erant of BCG therapy, were eligible for this study. 
Other key inclusion criteria were adequate renal (serum 
creatinine #1.5 × the upper limit of normal (ULN) or creatinine 
clearance $60 mLs/min), hepatic (alanine aminotransferase 
and aspartate   aminotransferase #2.5 × ULN and bil-
irubin levels #1.5 ×  ULN),  and  hematological 
(granulocytes $1500/µL, platelets $100,000/µL, and 
hemoglobin .8 g/dL) function. Women of child-bearing 
potential, and all men, must have agreed to use adequate 
contraception prior to and for the duration of the study.
Key exclusion criteria included patients with muscle-
invasive tumors, nodal involvement, or distant metastases; 
patients with a history of upper tract TCC, adenocarcinoma, 
or squamous cell carcinoma of the bladder; and patients with 
disease involving the prostatic ducts or stroma. Moreover, 
excluded were patients with a history of pelvic malignancy, 
hydronephrosis, or clinically significant abnormalities of the 
upper urinary tract and those who had undergone BCG ther-
apy within 6 weeks prior to the start of VB4-845 dosing.
Written informed consent was obtained from each partici-
pant before any study-related activity was performed. This 
study was conducted according to Section C.05.010 of Divi-
sion 5 of the Food and Drug Regulations of the   Government 
of Canada, ICH Harmonized Tripartite Guidelines for Good 
Clinical Practice, the Declaration of Helsinki (2002), and all 
local laws and regulations concerning clinical studies and 
the protection of study patients. Regulatory clearance for the 
study was obtained from the Biologics and Genetic Therapies 
Directorate of Health Canada in Canada.
study design and dose escalation
The study was an open-label, multicenter, dose-escalating 
trial of intravesically administered VB4-845. Eight dose 
levels were initially evaluated, starting at 0.1 mg once weekly 
for 6 consecutive weeks and escalating through 0.2, 0.33, 
0.66, 1.32, 2.64, 5.28, and 10.56 mg/dose. The maximum 
tolerated dose (MTD) was not reached; therefore, an addi-
tional escalation through 13.73, 17.85, 23.20, and 30.16 mg 
was undertaken. Each dose was administered to the bladder 
through a catheter and held for 2 h prior to voiding. Safety 
data from each dose cohort was evaluated after 3 weeks 
of treatment before proceeding to the next dose cohort. 
Dose-limiting toxicity (DLT) was defined as the occurrence 
of treatment-related AEs, including intractable cystitis 
persisting for more than 1 week associated with severe 
pain, urgency, and/or frequency not relieved by measures 
considered to be routine standard of care according to each 
clinical site; significant hematuria leading to clot obstruction; 
Grade 4 flu-like symptoms; Grade 3 or higher hematological 
toxicity (if it is a two grade increase from baseline); or any Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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other Grade 3 nonhematological toxicity (with the exception 
of alopecia). If two patients experienced a DLT at any dose, 
that dose would be defined as the MTD.
Patient evaluation
Patients were evaluated at every visit by physical exam 
and assessment of vital signs. Urinalysis was performed, 
and blood was collected for biochemistry and hematology. 
Concomitant medications were recorded. Specific additional 
evaluations were performed depending on the timing of the 
visit, as described below.
Pretreatment screening evaluations were conducted within 
4 weeks of the baseline visit and included medical history, 
pregnancy test, 12-lead electrocardiogram, and assessment 
of Karnofsky performance status. Tumors were evaluated   
by cystoscopy/photography, cytology, and biopsy. Cytopa-
thology and biopsy pathologic examinations were performed 
locally and not at a central laboratory. Immunohistochemistry 
on snap-frozen tissue samples was performed at a single facil-
ity to determine whether tumors were EpCAM positive.
In addition to the evaluations performed at every study 
visit, patients were monitored for AEs for 3 h following 
drug administration on days 1, 8, 15, 22, 29, and 36. The 
toxicity grade of any AE was classified according to the 
National Cancer Institute Common Toxicity Criteria, Ver-
sion 3. AEs were considered to be treatment related by the 
investigators if they were possibly, probably, or definitely 
related to VB4-845 administration. On day 2, AEs and con-
comitant medications were evaluated by interview.
The last visit occurred 4–6 weeks after the final treatment. 
Additional assessments performed included pregnancy test, 
12-lead electrocardiogram, and Karnofsky performance sta-
tus. To evaluate tumor response, cystoscopy/photography and 
cytology were performed. A biopsy was required if the cystos-
copy revealed lesions suspicious for malignancy, or cytology 
results were suspicious or positive for malignancy.
Pharmacokinetics and immunogenicity
Blood samples for pharmacokinetic analysis were taken on day 
1 prior to and 1, 2, and 3 h postdosing. Predose samples were 
also taken on days 8, 15, 22, 29, and 36. For each sample, 3 mL 
of venous blood was collected into a tube containing lithium 
heparinate and placed on ice. VB4-845 plasma levels were mea-
sured using a GLP-validated, MTS-based, potency assay.18 The 
assay detects intact VB4-845 by its ability to kill the EpCAM-
positive cell line CAL-27, where the measured IC50 is directly 
proportional to the concentration of intact drug. The assay was 
shown to have a lower limit of detection of 14 pg/mL.
Blood samples for assessing humoral immune reactivity 
to VB4-845 were taken prior to dosing on days 1, 8, 15, 22, 
29, 36, and at the final study visit. Samples were collected as 
for the pharmacokinetic analysis, and antibody titers to the 
scFv and ETA252–608 portions of the fusion protein (human anti-
human antibodies (HAHA) and human anti-Pseudomonas 
antibodies (HAPA)) were measured using an enzyme-linked 
immunosorbent assay.18 Responses were expressed as the 
geometric mean of measurable titers at each time point.
Evaluation of efficacy
Tumor response was assessed on evaluable patients 4–6 weeks 
following the last dose of VB4-845. The   evaluation was based 
on cytology, cystoscopy, and, if required, biopsy. Complete 
response was defined as nonpositive urinary cytology and 
either normal cystoscopy or abnormal cystoscopy with 
negative biopsy.
Results
Patient characteristics
Sixty-four patients were enrolled in this study. All participants 
were Caucasian with a median patient age of 69; 78% were 
men and 22% were women (Table 1). All patients evaluated 
for efficacy (61/64) had previously received BCG therapy, 
with 95% of the patients having had two or more bladder 
cancer recurrences. Based on their previous BCG treatment 
Table 1 Patient characteristics
Characteristic Number of patients 
(N = 64)
gender
  Male 50 (78)a
  Female 14 (22)
Disease duration
  1–4 years 43 (67)
 . 4 years 21 (33)
number of recurrences
 , 2 3 (5)
 $ 2 61 (95)
Prior Bcg cycles
 0 2 (3)
 1 27 (42)
 $ 2 35 (55)
Last Bcg cycleb
 . 6 months 40 (63)
 # 6 months 22 (34)
Tumor stage at baseline
  Ta 30 (47)
  T1 17 (27)
  Tis 17 (27)
Notes: aPercentages are shown in parentheses. The median patient age was 69 years 
with patient ages ranging 50–87 years; bTwo patients had not received Bcg.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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history, only five patients were considered to have been 
enrolled as BCG intolerant rather than BCG refractory. All 
patients had Grade 2 or 3, stage Ta or T1, TCC, and/or TIS, 
and, except for two cases, all papillary tumors had been previ-
ously resected 7–28 days prior to the first dose of study drug. 
Of note, as this study was carried out prior to the widespread 
adoption of re-transurethral resection (re-TUR) of TaT1, 
high-grade NMIBC in clinical practice, and its inclusion in 
standard treatment guidelines, re-TUR of T1 tumors was not 
performed. All tumors showed immunohistological evidence 
of EpCAM-positive membrane staining (Figure 1). Risk 
factors for progression present in the patient population are 
summarized in Table 2. At baseline, 98% of patients had at 
least one factor associated with disease progression, and 64% 
of these individuals had three or more risk factors.
Dose escalation and MTD
VB4-845 was administered to the bladder via catheter once 
a week for 6 consecutive weeks, followed by 4–6 weeks 
without treatment. An MTD was not determined from the 
initial dose escalation as no DLT was reported; therefore, 
additional dose cohorts were added as described above, and, 
again, all patients received all six scheduled doses without 
any DLT. The number of patients per dose cohort is sum-
marized in Table 3.
safety
Forty-one of the 64 patients (64%) experienced an AE during 
the course of the study. Twenty-one (33%) patients experi-
enced only AEs that were assessed by the investigator as 
unrelated to study treatment. Classifying the AEs as unrelated 
to the study drug was decided after considering the temporal 
relationship of the onset of the event to the administration 
of the study drug, whether the event could be explained by 
concomitant medications or concurrent disease, the response 
to withholding the study drug, and the response to rechallenge 
with the study drug. These included, but were not limited to, 
urinary tract infection, incontinence, nocturia, pharyngola-
ryngeal pain, and bladder spasm. The remaining 20 patients 
(31%) experienced AEs judged to be related to VB4-845 
administration. The most common treatment-related AEs 
Figure  1  immunohistochemical  staining  of  epcAM  on  Tcc  of  the  bladder. 
Tissue samples were formalin fixed, paraffin embedded, and mounted onto coated 
microscope slides. Test slides containing A) normal bladder, C) epcAM-negative 
Tcc, and E) epcAM-positive Tcc tissue sections were incubated with the primary 
antibody  VB4-845  and  VB4-845  cell  surface  binding  detected  with  a  secondary 
antibody, rabbit anti-Pseudomonas eTA (sigma, catalog no. P2318, st. Louis, MO, 
USA). Specificity of EpCAM staining was demonstrated with the corresponding 
control  slides,  B)  normal  bladder,  D)  epcAM-negative  Tcc,  and  F)  epcAM-
positive Tcc, treated only with the secondary antibody. Membranous staining (2+) 
is only apparent with the epcAM-positive Tcc tissue section E) incubated with both 
VB4-845 and the secondary antibody. All pictures are shown at 100 × magnification.
Table 2 Disease risk factors at baseline
Risk factor Number 
of patients 
N = 64
Aggressive histology (Ta, Tis or T1 grade 3) 39
$2 Disease recurrences 61
Prior Bcg failures $2 cycles 35
Last Bcg failure #6 months 22
Disease duration .4 years 21
number of patients with $1 risk factor at baseline 63/64 (98)a
number of patients with $3 risk factors at baseline 41/64 (64)
Note: aPercentages are shown in parentheses.
Table 3 number of patients per dose cohort
Dose level (mg) Number of patients
0.1 4
0.2 3
0.33 5
0.66 5
1.32 3
2.64 5
5.28 6
10.56 5
13.73 3a
17.85 7
23.20 10
30.16 8b
Total 64
Notes: aOne  treatment-unrelated  death.  This  patient  was  not  included  in  the 
assessment for efficacy; bTwo patients had not received prior Bcg treatment and 
were not included in the efficacy assessment.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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were dysuria and hematuria (Table 4). Systemic AEs included 
fatigue, fever and chills, loss of appetite, myalgia, dizziness, 
and nausea. The frequency of treatment-related AEs did not 
increase with dose escalation (Figure 2). All treatment-related 
AEs were Grade 1 or 2, with the exception of one Grade 3 
occurrence of hematuria that was reported as possibly related 
to VB4-845 administration. This event was not reported as 
a DLT as the investigator judged it to be related to aspirin 
use, and the patient experienced no AEs with subsequent 
VB4-845 dosing. There were no cases where the occurrence 
of AEs required discontinuation of treatment, and no patient 
experienced a serious AE related to the administration of 
VB4-845. There was one patient death due to cardiac failure, 
which occurred 3 weeks after the last dose of VB4-845. This 
death was assessed by the investigator as unrelated to study 
treatment and attributed to long-standing coronary artery 
disease, previous myocardial infarction, and hypertension.
Pharmacokinetics
Postinstillation plasma levels of VB4-845 were measured 
in 63 patients, except at the final visit where samples were 
  provided by 61 patients. In almost all patients, VB4-845 
plasma levels were below the limit of detection of the 
assay (14 pg/mL) at all time points examined. VB4-845 
was   detectable in only two patients: one had levels of 19 
and 17 pg/mL at 1 h after VB4-845 instillation and on day 
8 prior to dosing, respectively, and the other had a level of 
18 pg/mL at the 1 h time point.
immunogenicity
The immunogenicity of  VB4-845 was examined by ana-
lyzing HAPA and HAHA titers in blood samples taken 
at specified time points during the trial (Table 5). HAPA 
response was more vigorous, as patients developed a 
measurable titer earlier; the majority of patients exhibited 
HAPA by day 29, with 77% (47/61) having a measur-
able titer at final visit. In contrast, only 16% (10/61) of 
patients had HAHA by the end of the study. HAPA titers 
were also generally higher, with a mean maximum titer of 
20,512 versus 3373 for HAHA responses. A comparison of 
mean titers of the HAPA and HAHA responses measured 
in samples taken on the final visit showed no significant 
difference between responders and nonresponders (data 
not shown). The absence of any apparent relationship 
between antibody titer and response to treatment suggests 
that the immune response was not detrimental to clinical   
outcome.
Table 4 Adverse events related to VB4-845 administration
Adverse event Number of patients per gradea
Grade 1 Grade 2 Grade 3
Local
Dysuria 7 2 0
hematuria 5 1 1
Pollakiuria 2 2 0
Micturition urgency 3 1 0
enuresis/nocturia 2 1 0
Urinary 1 2 0
retention/incontinence
Bladder spasm 2 0 0
Bladder hemorrhage 1 1 0
instillation site abnormalities 1 0 0
Systemic
Fatigue 5 0 0
Pyrexia/chills 2 2 0
Anorexia/decreased appetite 2 2 0
or weight
Myalgia 2 1 0
nausea/vomiting 0 2 0
Dizziness 2 0 0
Dry mouth/tongue 2 0 0
nasopharyngitis/cough 2 0 0
hypotension 0 1 0
erythema/rash 1 1 0
Arthralgia 0 1 0
headache 0 1 0
Diarrhea 0 1 0
Alopecia/abnormal hair 1 1 0
growth
Pruritis 1 0 0
Dysgeusia 1 0 0
neck pain 1 0 0
Peripheral sensory 1 0 0
neuropathy
Note: alf a patient experienced an adverse event more than once, the event with the 
highest grade was tabulated. 
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Figure 2 Percentage of patients experiencing treatment-related adverse events 
(Aes) by grade per dose level. Of the 41 patients experiencing Aes, 20 patients 
experienced Aes related to treatment. Aes at each dose level are proportioned 
according to the grade level. if a patient experienced an Ae more than once, only 
the event with the highest grade was included in the calculation. The dose levels 
and corresponding total number of Aes are as follows: 0.01, n = 9; 0.20, n = 0; 0.33, 
n = 6; 0.66, n = 12; 1.32, n = 1; 2.64, n = 9; 5.28, n = 6; 10.56, n = 1; 13.73, n = 6; 
17.85, n = 1; 23.20, n = 7; and 30.16, n = 2.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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Exploratory efficacy
Sixty-one patients were considered to be evaluable for effi-
cacy; two patients were excluded from the efficacy analysis 
due to an absence of BCG treatment prior to the study, and 
there was one study-unrelated death for whom no final tumor 
assessment was obtained.
Complete response based on tumor classification at 
baseline and dose group is summarized in Table 6. Overall, 
a complete response was achieved by 39% (24/61) of the 
patients. Of the patients with TIS, 29% achieved a complete 
response, while complete responses were observed in 44% 
and 43% of the patients with T1 and Ta, respectively. Of the 
five patients classified as BCG intolerant, only one (20%) 
had a complete response.
Given the limited number of patients per dose cohort, it was 
not possible to make definitive individual dose comparisons. 
In order to examine a potential dose response, patients were 
classified into three dose groups: (0.1 to ,1.0 mg) = lowest 
dose group; (1.0 to ,10.0 mg) = middle dose group; and 
($10.0 mg) = highest dose group. A comparison of the 
response rates in the lowest dose group versus the combined 
middle and highest dose group revealed a statistically sig-
nificant P-value of 0.0418.
Discussion
TCC is the most common cancer of the bladder, and most 
patients present with nonmuscle-invasive disease. Currently, 
BCG is the standard of care for this malignancy. Despite 
its well-documented therapeutic benefit, BCG therapy is 
delayed or discontinued in a large proportion of patients due 
to associated toxicity. In rare instances, patients can develop 
severe conditions associated with BCG infection, in some 
cases life-threatening, rendering BCG a nonviable treatment 
option. Termination of treatment due to adverse effects is not 
uncommon for intravesical therapies. In addition, for those 
patients who fail to respond to BCG therapy or experience 
early disease recurrence, alternative therapeutic options 
are limited. Given the potential for intolerance and the high 
rate of recurrence in patients with NMIBC, alternative treat-
ments are under investigation.
Targeted therapies limit drug exposure to only diseased 
cells, thereby minimizing drug-related toxicities. We have 
described a Phase I study of VB4-845, an anti-EpCAM 
scFv–ETA, administered intravesically to high-risk patients. 
Of the 75 patients initially screened for participation, 
74 (99%) showed EpCAM-positive disease. This high rate 
of EpCAM expression suggests that EpCAM represents a 
significant antigen for VB4-845-targeted therapy in patients 
with advanced NMIBC. Although not performed in this 
study, an examination of the expression levels of EpCAM in 
biopsy samples obtained from patients with residual disease 
following VB4-845 treatment might be informative and will 
be considered for future studies.
AEs experienced with VB4-845 were mild and easily man-
aged, and no AE required the discontinuation of treatment, 
even in the highest dose cohort. Although the presence of 
pre-existing lower urinary tract symptoms may make a deter-
mination of the frequency of AEs difficult, what is evident is 
that the relatively mild toxicities experienced with VB4-845 
are in direct contrast to other intravesical therapies where local 
and systemic toxicities can be treatment limiting. VB4-845 is 
a targeted therapy that exerts its effect via specific interaction 
with the cell surface antigen EpCAM. Although overexpressed 
on carcinoma cells, EpCAM expression is lower on normal 
tissue and limited to the basal layers rather than luminal sur-
faces. These features could minimize drug-related toxicities 
and may explain why related AEs were predominantly Grade 
1 and 2. It is also interesting to note that failure to reach an 
Table 5 Antibody responses to the eTA and scFv portions of 
VB4-845
Day HAPA response HAHA response
# Patientsa Mean  
titer 
(×103)
SE # Patientsa Mean  
titer 
(×103)
SE
8 1/63 2.512 n/A 0/63 0 n/A
15 12/63 17.060 1.596 2/63 1.462 1.161
22 27/63 14.222 1.380 6/63 2.408 1.196
29 37/63 17.140 1.309 7/63 2.700 1.303
36 45/63 18.408 1.276 8/63 3.662 1.312
55 47/61 20.512 1.241 10/61 3.373 1.132
Note: anumber of patients with a detectable response/number of patients evaluated. 
Mean titer is calculated as the geometric mean of all patients with a measurable titer 
at the given time point. 
Abbreviation: se, standard error.
Table 6 Tumor response by stage and dose group
Response classification Complete response   
rate
evaluable patients 24/61 (39)a
Tumor stage at baseline
  Tis 5/17 (29)
  T1 7/16 (44)
  Ta 12/28 (43)
Dose group
  0.1 mg–,1.0 mg 3/17 (18)
  1.0 mg–,10.0 mg 7/14 (50)
 $ 10.0 mg 14/30 (47)
Notes: aPercentages are shown in parentheses. P-value for lowest vs middle dose 
group = 0.1206. P-value for lowest vs highest dose group = 0.0622. P-value for 
lowest vs middle + highest dose groups combined = 0.0418.Drug Design, Development and Therapy 2010:4 submit your manuscript | www.dovepress.com
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MTD for VB4-845 over the dose range tested and the apparent 
absence of any relationship between the appearance of AEs 
and dose are in keeping with its excellent safety profile.
Pharmacokinetic analyses indicated that VB4-845 was not 
systemically absorbed and remained within the bladder until 
elimination by voiding. This is anticipated, given the integrity 
of the bladder and the molecular size of VB4-845 (∼69 kDa).
VB4-845 was shown to be immunogenic with the toxin 
portion eliciting the more vigorous response. Given the 
humanization of the scFv antibody fragment and entirely 
foreign nature of the bacterial toxin, the more intense immune 
response against the toxin was expected. A similar pattern of 
immune response was observed with LMB-2, a scFv–ETA 
immunotoxin, whereby more patients exhibited a stronger 
response to the ETA moiety than to the scFv portion.20 
Despite the observed immunogenicity, the development of 
an immune response was not considered to have any bearing 
on clinical outcome, as there was no apparent relationship 
between antibody titer and response to treatment. Rather, 
the presence of circulating antibodies to VB4-845 may, in 
fact, limit any systemic exposure that may occur by rapidly 
clearing any drug that may enter circulation. Together, the 
specificity of VB4-845 and its lack of systemic exposure 
translate to a very acceptable safety profile.
Although the Phase I trial was primarily designed to 
determine the MTD, tumor response was assessed as a single 
efficacy endpoint at 3 months to elucidate any observable 
trends. Although dosing was not optimized for therapeutic 
benefit, complete responses were observed across all tumor 
stages and dose groupings.  Although it is not possible to draw 
definitive conclusions between individual dose and response 
to treatment, when examined according to dose groups, the 
data are suggestive of an increased response with higher 
doses. Although no direct examination of receptor occupancy 
has been performed, the dose range of VB4-845 adminis-
tered far exceeds the drug concentration required to achieve 
.99% cell killing in EpCAM-positive bladder tumor cell 
lines. Therefore, it is possible that the tumor response may be 
saturated at the higher doses. It should be noted that the short 
duration of follow-up is a significant limitation with respect to 
assessing efficacy; thus, efficacy results reported in this study 
are considered preliminary and serve only to support further 
clinical trials with longer follow-up assessments.
Conclusions
Intravesical therapy with the anti-EpCAM fusion protein 
VB4-845, for the treatment of NMIBC was extremely well 
tolerated. AEs were generally mild and very manageable 
with no patients experiencing any serious AEs related to 
VB4-845 therapy. The lack of detectable postinstillation 
plasma levels in the vast majority of patients indicates that the 
drug is effectively held within the bladder and not systemi-
cally absorbed. Although most patients developed antibody 
titers, the data obtained in this study showed no evidence of 
detrimental effects on clinical outcome associated with the 
immune response. Preliminary efficacy results from this high-
risk, often treatment-refractory, patient population suggest 
that VB4-845 can safely inhibit tumor growth in patients 
with EpCAM-positive, high-grade NMIBC. This promising 
finding warrants investigation in a larger clinical trial with 
optimized dosing.
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